1. Introduction {#s0005}
===============

MetSyn is an asymptomatic, pathophysiological state characterised by obesity, insulin resistance, hypertension, dysglycaemia, and dyslipidaemia ([@bb0015]). While several criteria and definitions have been used to identify MetSyn ([@bb0015], [@bb0090], [@bb0010], [@bb0020]); it is generally agreed that a combination of three or more of the following components must be present: large waist circumference, elevated triglycerides, low HDL-cholesterol, raised blood pressure, and elevated fasting blood glucose.

The International Diabetes Federation (IDF) estimates that ≈ 25% of the world\'s population has MetSyn ([@bb0190]) although this estimate varies widely due to the age, ethnicity, and gender of the population studied ([@bb0145]). Having a slightly raised value of a MetSyn component at a younger age increases the future risk for MetSyn later in life ([@bb0095]). Therefore it is important to establish the prevalence of MetSyn components in young adults (18--30 years), as the presence of a MetSyn component could represent a lifetime of increased cardiovascular disease risk. Moreover, the early identification of MetSyn components could lead to targeted interventions to prevent the development of the syndrome, and thus reduce cardiovascular disease risk in later life.

Therefore, we performed a pooled analysis of previous literature that examined the prevalence of MetSyn and components of MetSyn in young adults with the purpose of determining: 1) the global prevalence of MetSyn in young adults, and 2) the most prevalent MetSyn component in this population.

2. Methods {#s0010}
==========

PubMed, SCOPUS and Medline were searched using the terms "Metabolic Syndrome", "Prevalence", and "Young Adults" combined with the Boolean operator "AND". The search was repeated using the term "College Students" instead of "Young Adults" and the results combined. Duplicates from the returned reference lists were discarded and the list was consolidated into one list from the three databases.

Abstracts from the returned references were downloaded and were kept if the abstract indicated that the article may contain data relating to MetSyn and apparently healthy young adults. The remaining articles were downloaded in full and analysed for specific data relating to MetSyn in young adults. Studies were included if 1) Participants were sampled on the basis of being apparently healthy, free of chronic conditions, or having specific anthropometric characteristics; 2) Data were available in the age range of 18--30 years old; 3) The prevalence for MetSyn was supplied or able to be calculated; 4) The NCEP-ATP III criteria ([@bb0020]), Revised NCEP-ATPIII (referred to here as AHA/NHBLI) criteria ([@bb0090]), International IDF criteria ([@bb0010]) or the harmonized criteria ([@bb0015]) for MetSyn were used ([Table 1](#t0005){ref-type="table"}). In addition, the article had to be written in English and accessible either through open access or our institution\'s library subscription that has access to 1200 + databases and 98,000 e-journals. All papers were cross checked to ensure that data were not used across multiple studies.Table 1Metabolic syndrome criteria according to Harmonized ([@bb0015]), IDF ([@bb0010]), NCEP-ATPII ([@bb0020]) and AHA/NHBLI criteria ([@bb0090]).Table 1MetSyn CriteriaHarmonizedIDFNCEP-ATPIIIAHA/NHBLIAny three or more of:WC ≥ 94 cm (male)\
WC ≥ 80 cm (female)Any three or more of:Any three or more of:WCEthnic specific cut pointsAnd two or more of:≥ 102 cm (male)\
≥88 cm (female)≥ 102 cm (male)\
≥88 cm (female)HDL\< 1.03 mmol/L (male)\
\<1.29 mmol/L (female)\
OR taking medication for reduced HDL\< 1.03 mmol/L (male)\
\<1.29 mmol/L (female)\
OR taking medication for reduced HDL\< 1.03 mmol/L (male)\
\<1.29 mmol/L (female)\
OR taking medication for reduced HDL\< 1.03 mmol/L (male)\
\<1.29 mmol/L (female)\
OR taking medication for reduced HDLTG≥ 1.7 mmol/L or medication for elevated TG≥ 1.7 mmol/L or medication for elevated TG≥ 1.7 mmol/L or medication for elevated TG≥ 1.7 mmol/L or medication for elevated TGBP≥ 130 mm Hg Systolic BP or ≥ 85 mm Hg Diastolic BP or on BP-lowering medication≥ 130 mm Hg Systolic BP or ≥ 85 mm Hg Diastolic BP or on BP-lowering medication≥ 130 mm Hg Systolic BP or ≥ 85 mm Hg Diastolic BP or on BP-lowering medication≥ 130 mm Hg Systolic BP or ≥ 85 mm Hg Diastolic BP or on BP-lowering medicationFBG≥ 5.6 mmol/L or antidiabetic medication≥ 5.6 mmol/L or antidiabetic medication≥ 6.1 mmol/L or antidiabetic medication≥ 5.6 mmol/L or antidiabetic medication[^1]

Data relating to MetSyn and MetSyn components in 18--30 year old adults were extracted from the reviewed articles and MetSyn and MetSyn component prevalence was calculated using the four different definitions. The results were tabulated ([Table 2](#t0010){ref-type="table"}).Table 2Prevalence of metabolic syndrome and metabolic syndrome components in 26,609 young adults.Table 2AuthorCountryTotal (n)MetSynWCHDLTGBPFBGHarmonized[@bb0005]UAE55538 (6.8)101 (18.2)271 (48.8)8 (1.4)30 (5.4)54 (9.7)[@bb0035]Jamaica7466 (0.8)108 (14.5)343 (46.0)4 (0.5)154 (20.6)8 (1.1)[@bb0070]Jamaica83910 (1.2)134 (16.0)393 (46.8)5 (0.6)56 (6.7)10 (1.2)[@bb0080][a](#tf0005){ref-type="table-fn"}Spain29218 (6.2)81 (27.7)49 (16.8)24 (8.2)48 (16.4)11 (3.8)[@bb0100]India48612(2.5)51 (10.5)150 (30.9)27 (5.6)15 (3.1)31 (6.4)[@bb0130]Taiwan35524 (6.8)63 (17.7)46 (20.6)32 (9.0)123 (34.6)4 (1.1)[@bb0135]Kenya909 (10.0)17 (18.9)47 (52.2)3 (3.3)51 (56.7)1 (1.1)[@bb0160]China32322 (6.8)180 (55.7)63 (19.5)40 (12.4)20 (6.2)22 (6.8)[@bb0170][a](#tf0005){ref-type="table-fn"}Brazil2031242 (9.0)646 (31.8)851 (41.9)254 (12.5)465 (22.9)73 (3.6)[@bb0230][a](#tf0005){ref-type="table-fn"}Philippines861108 (12.5)173 (20.1)467 (54.2)171 (19.9)127 (14.8)144 (16.7)Overall6578430 (6.5%)1554 (23.6%)2707 (41.2%)568 (8.6%)1089 (16.6%)358 (5.4%)NCEP --ATPIII[@bb0065]Turkey130693 (7.1)182 (13.9)318 (21.3)183 (14.0)424 (32.5)25 (1.9)[@bb0095][a](#tf0005){ref-type="table-fn"}Turkey8410 (11.9)25 (29.8)19 (22.6)24 (28.6)20 (23.8)11 (13.1)[@bb0110]USA1631 (0.6)3 (1.8)22 (13.5)4 (2.5)2 (1.2)3 (1.8)[@bb0155][a](#tf0005){ref-type="table-fn"}China2532101 (4.0)79 (3.1)742 (29.3)241 (9.5)519 (20.5)58 (2.3)[@bb0165]India47341 (8.7)76 (16.1)184 (38.9)37 (7.8)123 (26.0)42 (8.9)[@bb0175][a](#tf0005){ref-type="table-fn"}Finland109938 (3.5)51 (4.6)212 (19.3)31 (2.8)565 (51.4)25 (2.3)[@bb0205]Russia86223 (2.7)19 (2.2)266 (30.9)83 (9.6)149 (17.3)6 (0.7)[@bb0220]India858 (9.4)18 (21.2)53 (62.4)18 (21.2)5 (5.9)7 (8.2)[@bb0225]Turkey28518 (6.3)14 (4.9)40 (14.0)115 (40.4)25 (8.8)13 (4.6)Overall6889333 (4.8%)467 (6.8%)1856 (26.9%)736 (10.7%)1832 (26.6%)190 (2.8%)IDF[@bb0025][a](#tf0005){ref-type="table-fn"}Qatar20316 (7.9)16 (7.9)43 (21.2)30 (14.8)34 (16.7)8 (3.9)[@bb0050]Brazil71128 (3.9)90 (12.7)313 (44.0)35 (4.9)71 (10.0)35 (1.4)[@bb0210][a](#tf0005){ref-type="table-fn"}Brazil3599240 (6.7)618 (17.2)694 (19.3)598 (16.6)883 (24.5)1322 (36.7)[@bb0080][a](#tf0005){ref-type="table-fn"}Spain29218 (6.2)81 (27.7)49 (16.8)24 (8.2)48 (16.4)11 (3.8)[@bb0095][a](#tf0005){ref-type="table-fn"}Turkey8416 (19.0)25 (29.8)19 (22.6)24 (28.6)20 (23.8)11 (13.1)[@bb0105][a](#tf0005){ref-type="table-fn"}Norway161519 (1.2)414 (25.6)459 (28.4)221 (13.7)499 (30.9)179 (11.1)[@bb0120][a](#tf0005){ref-type="table-fn"}USA3002 (0.7)8 (2.7)73 (24.3)27 (9.0)11 (3.7)27 (9.0)[@bb0140]India25055 (22.0)139 (55.6)93 (37.2)71 (29.2)21 (8.4)44 (17.6)[@bb0155][a](#tf0005){ref-type="table-fn"}China2532147 (5.8)79 (3.1)742 (29.3)241 (9.5)519 (20.5)58 (2.3)[@bb0170][a](#tf0005){ref-type="table-fn"}Brazil2031242 (11.9)646 (31.8)851 (41.9)254 (12.5)465 (22.9)73 (3.6)[@bb0175][a](#tf0005){ref-type="table-fn"}Finland109975 (6.8)134 (12.2)212 (19.3)31 (2.8)565 (51.4)221 (20.1)[@bb0230][a](#tf0005){ref-type="table-fn"}Philippines861108 (9.1)173 (20.1)467 (54.2)171 (19.9)127 (14.8)144 (16.7)[@bb0235][a](#tf0005){ref-type="table-fn"}USA37635 (9.3)43 (11.4)73 (19.4)21 (5.6)38 (10.1)42(11.2)Overall13,953971 (7.0%)2466 (17.7%)4088 (29.3%)1750 (12.5%)3301 (23.7%)2150 (15.4%)AHA/NHBLI[@bb0025][a](#tf0005){ref-type="table-fn"}Qatar20315 (7.4)16 (7.9)43 (21.2)30 (14.8)34 (16.7)8 (3.9)[@bb0040]China2001 (0.5)4 (2.0)19 (9.5)13 (6.5)24 (12.0)6 (3.0)[@bb0210][a](#tf0005){ref-type="table-fn"}Brazil3599213 (5.9)269 (7.5)694 (19.3)598 (16.6)883 (24.5)610 (16.9)[@bb0055]USA20714 (6.8)12 (5.8)98 (47.3)28 (13.5)34 (16.4)15 (7.2)[@bb0150]Netherlands64248 (7.5)78 (12.1)187 (29.1)50 (7.8)274 (42.7)75 (11.7)[@bb0075]USA1897 (3.7)14 (7.4)38 (20.1)33 (17.5)4 (2.1)14 (7.4)[@bb0080][a](#tf0005){ref-type="table-fn"}Spain29210 (3.4)31 (10.6)49 (16.8)24 (8.2)48 (16.4)11 (3.8)[@bb0105][a](#tf0005){ref-type="table-fn"}Norway161519 (1.2)414 (25.6)459 (28.4)221 (13.7)499 (30.9)179 (11.1)[@bb0120][a](#tf0005){ref-type="table-fn"}USA3004 (1.3)8 (2.7)73 (24.3)27 (9.0)11 (3.7)27 (9.0)[@bb0185]USA161081 (5.0)209 (130)467 (29.0)258 (16.0)403 (25.0)64 (4.0)[@bb0180]USA2103103 (4.9)94 (4.5)538 (25.6)350 (16.6)681 (32.4)177 (8.4)[@bb0195]Iran20313 (6.4)26 (12.8)85 (41.9)47 (23.2)1 (0.5)35 (17.2)[@bb0200]Iran93470 (7.5)31 (9.7)714 (76.4)246 (26.3)56 (6.0)74 (7.9)[@bb0235][a](#tf0005){ref-type="table-fn"}USA37645 (12.0)43 (11.4)73 (19.4)21 (5.6)38 (10.1)42 (11.2)Overall12,473643 (5.2%)1309 (10.5%)3537 (28.4%)1946 (15.6%)2990 (24.0%)1337 (10.7%)[^2][^3][^4]

3. Results {#s0015}
==========

From the initial search, 1276 unique citations were returned, of which 992 studies were immediately discarded based on the title or abstract. The remaining 284 studies were evaluated against the inclusion criteria. Thirty-four papers were included in the final review with 11 studies ([@bb0030], [@bb0210], [@bb0080], [@bb0095], [@bb0105], [@bb0120], [@bb0155], [@bb0170], [@bb0175], [@bb0230], [@bb0235]) providing MetSyn data based on multiple definitions. Data from 26,609 different people aged between 18 and 30 years from 17 countries were available for analysis -- see table for individual and grouped prevalence data. Please note that the combined number of observations for all MetSyn definitions is \> 26,609 due to the inclusion of studies using multiple definitions.

Overall MetSyn prevalence was 4.8% (NCEP-ATPIII, *n* = 333/6889) 5.2% (AHA/NHBLI, *n* = 643/12473), 7.0% (IDF, *n* = 971/13953) and 6.5% (harmonized, *n* = 430/6578). Atherogenic dyslipidaemia defined as low HDL was the most prevalent MetSyn component regardless of the criteria used (26.9--41.2%) followed by raised blood pressure (16.6--26.6%), abdominal obesity (6.8--23.6%), atherogenic dyslipidaemia defined as raised triglycerides (8.6--15.6%), and raised fasting glucose (2.8--15.4%) ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Prevalence of metabolic syndrome and metabolic syndrome components in 26,609 young adults according to four metabolic syndrome criteria.MetSyn -- metabolic syndrome; WC -- abdominal obesity; HDL - atherogenic dyslipidaemia (low HDL); TG - atherogenic dyslipidaemia (raised triglycerides); BP - raised blood pressure; FBG -- raised fasting glucose.Fig. 1

4. Discussion {#s0020}
=============

This study provides new information about MetSyn in young adults in two important ways. First, pooled analysis of a large sample suggests that 5--7% of young adults have MetSyn. While the prevalence is less than the IDF estimated prevalence in all adults of 25% worldwide ([@bb0190]), the development of MetSyn early in adulthood can lead to an elevated lifetime burden of cardiovascular disease risk. Second, one third of all participants had at least one component of MetSyn with low HDL being the most prevalent component. This latter finding raises the possibility that low HDL may be a key marker identifying early pathology associated with the development of MetSyn.

Prevention of the development of the first MetSyn component may have significant public health benefits as the presence of one component is predictive of the development of MetSyn ([@bb0045]). Low HDL cholesterol occurs primarily due to increased triglyceride formation reducing cholesterol content of the lipoprotein core ([@bb0060]). Accordingly, it was expected that a higher prevalence of raised triglyceride levels would be observed in the current findings; however, this did not occur. We speculate that this could reflect currently unknown mechanisms regarding HDL metabolism or a triglyceride cut-off point not calibrated to changes in HDL levels in young adults. Regardless, while low HDL is not universally exhibited in all young adults with at least one MetSyn component, our findings demonstrate that low HDL is the most frequently exhibited MetSyn component regardless of MetSyn definition and may indicate the initiation of pathphysiological processes that underpin the development of MetSyn for many young adults. Further research should be undertaken to identify why low-HDL is the most common component of MetSyn in young adults.

MetSyn component prevalence was lower than reported for European adults from a more diverse and older aged population than the current study ([@bb0240]). Approximately 45% of 19--39 year old adults had the BP component, 25% the WC component, 25% TG component, and 20% with HDL component of MetSyn ([@bb0240]). Vishram et al. also report an increased prevalence of BP and WC in males with increased age with a peak prevalence of elevated TGs and reduced HDL in the 40--49 year age bracket with a subsequent decline in older age ranges (50--59, 60--78 years). A similar pattern was observed in females except TG prevalence increased with age and only HDL prevalence is decreased in ages above 40--49 years. Therefore, prevalence of MetSyn components in young adults is expected to increase up to the age of 50.

While overall MetSyn prevalence was similar between the four MetSyn definitions, a wide range of prevalence was present for each MetSyn component. Differences in WC prevalence can be partially explained by the use of ethnic specific thresholds in the harmonized and IDF definitions but the difference in HDL, BP, and FBG prevalence, cannot be explained by the definition. Therefore, it is possible that these observations indicate young adults from different ethnicities are more prone to develop different components of MetSyn. Therefore, a possibility worth exploring is that all MetSyn component thresholds may be ethnic specific and thus specific ethnic thresholds for each MetSyn component may need to be developed to accurately assess MetSyn. This is similar to current recommendations of using ethnic specific thresholds for WC.

5. Conclusion {#s0025}
=============

MetSyn prevalence ranges from 5 to 7% in young adults. Low HDL is the most prevalent component of MetSyn in young adults and thus may also be the first detectable component of MetSyn in many young adults. Exploring the importance and significance of low HDL in young adults may have considerable public health benefit as interventions aimed at improving low HDL cholesterol levels could reduce future incidence of MetSyn and subsequent clinical disease.
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[^1]: MetSyn -- metabolic syndrome; WC -- abdominal obesity; HDL - atherogenic dyslipidaemia (low HDL); TG - atherogenic dyslipidaemia (raised triglycerides); BP - raised blood pressure; FBG -- raised fasting glucose.

[^2]: Data are expressed as n (%).

[^3]: MetSyn -- metabolic syndrome; WC -- abdominal obesity; HDL - atherogenic dyslipidaemia (low HDL); TG - atherogenic dyslipidaemia (raised triglycerides); BP - raised blood pressure; FBG -- raised fasting glucose.

[^4]: Indicates study used more than one definition of MetSyn and is included multiple times.
